Up to the present time 35 patients with multiple myeloma have been subjected to treatment with "stilbamidine" (4.4'—stilbenedicarboxamidine). In this article experiences which have been collected will be reviewed and morphologic changes in the cytoplasm of the myeloma cells which result from this treatment will be discussed.
"Stilbamidine" can be given intravenously. If no veins are accessible the drug can also be injected intramuscularly. After a first injection-of 50 mg. and a second injection of 100 mg., each subsequent injection should amount to 150 mg. A total of fifteen to twenty injections is usually sufficient to alleviate the pain. "Stilbamidine" should not be autoclaved or filtered before use. The crystal-like substance should be weighed out. For intravenous use it is dissolved in 10 cc. of sterile water; for intramuscular use in 5 cc. of a 2 per cent solution of procaine hydrocholoride. Intramuscular injections should be
SNAPPER I. TREATMENT OF MULTIPLE MYELOMA WITH "STILBAMIDINE": Clinical Results and Morphologic Changes. JAMA. 1948;137(6):513–516. doi:10.1001/jama.1948.02890400017003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: